We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, GSK (GSK - Free Report) closed at $35.98, marking a +0.5% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.73% for the day. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.93%.
Coming into today, shares of the drug developer had lost 5.07% in the past month. In that same time, the Medical sector lost 4.57%, while the S&P 500 lost 2.29%.
Market participants will be closely following the financial results of GSK in its upcoming release. The company plans to announce its earnings on November 1, 2023. On that day, GSK is projected to report earnings of $1.06 per share, which would represent a year-over-year decline of 2.75%. In the meantime, our current consensus estimate forecasts the revenue to be $9.72 billion, indicating a 5.41% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.78 per share and a revenue of $36.88 billion, representing changes of +9.25% and -7.12%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GSK. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.48% lower within the past month. Right now, GSK possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that GSK has a Forward P/E ratio of 9.48 right now. This signifies a discount in comparison to the average Forward P/E of 16.06 for its industry.
It's also important to note that GSK currently trades at a PEG ratio of 1.89. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.77.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know
In the latest trading session, GSK (GSK - Free Report) closed at $35.98, marking a +0.5% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.73% for the day. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.93%.
Coming into today, shares of the drug developer had lost 5.07% in the past month. In that same time, the Medical sector lost 4.57%, while the S&P 500 lost 2.29%.
Market participants will be closely following the financial results of GSK in its upcoming release. The company plans to announce its earnings on November 1, 2023. On that day, GSK is projected to report earnings of $1.06 per share, which would represent a year-over-year decline of 2.75%. In the meantime, our current consensus estimate forecasts the revenue to be $9.72 billion, indicating a 5.41% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.78 per share and a revenue of $36.88 billion, representing changes of +9.25% and -7.12%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GSK. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.48% lower within the past month. Right now, GSK possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that GSK has a Forward P/E ratio of 9.48 right now. This signifies a discount in comparison to the average Forward P/E of 16.06 for its industry.
It's also important to note that GSK currently trades at a PEG ratio of 1.89. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.77.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.